Mandy Xu

Company: VelaVigo

Job title: Vice President, Head of Antibody Therapeutic Discovery

Seminars:

12:00pm VBC104: A First-in-class CD79b/CD20 Targeted Bi-specific Antibody Drug Conjugate (ADC) with Superior Efficacy vs 1st line CD79b ADC in DLBCL, RT, FL, MCL, MZL and Beyond 12:00 pm

The anti-CD79b ADC, Polatuzumab Vedotin (PV), has demonstrated significant clinical benefits in B cell lymphoma and is approved for the first-line therapy. However, there remains a strong unmet medical need for PV-resistant patients and those with Richter's syndrome VBC104 is a first-in-class bi-specific antibody-drug conjugate (ADC) targeting both CD79b and CD20. It has the potential…Read more

day: Bispecific ADC Seminar Day